Please login to the form below

Not currently logged in
Email:
Password:

GSK commended for community work

GlaxoSmithKline has become one of the first companies to be awarded the new 'CommunityMark' by UK organisation
GlaxoSmithKline (GSK) has become one of the first companies to be awarded the new 'CommunityMark' by UK organisation, Business in the Community (BITC), after being assessed alongside leading retailers, banks and professional service firms.

BITC's CommunityMark is a new initiative that rewards companies for their investment in community and is endorsed by the government and voluntary sector leaders. It recognises firms that have achieved the highest standards in this area and GSK is the only manufacturer that has, to date, received the award.

GSK was given the CommunityMark for its work at local and national level in the UK as well as for its international programmes.

"The rigorous assessment process employed by BITC makes the recognition of our long-term commitment to community investment all the more significant. We are proud to have been awarded the CommunityMark," said Andrew Witty, chief executive of GSK. "The combined efforts of developing innovative medicines and vaccines alongside our work with communities can have a genuine impact on society."

The assessment process for the award saw GSK having to demonstrate to a review panel that it has a long-term, high-level commitment to community investment by using examples such as its positive action programme for HIV/AIDS. The award is applicable for a period of three years, after which GSK can apply for it to be renewed.

In total, 21 UK companies have been granted a CommunityMark by the BITC.

8th July 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics